Type 2 Diabetes

New post hoc data from the STEP 1 and 4 trials show an approximate 60% risk reduction of type 2 diabetes over 10 years versus placebo.

A new report from the CDC that examined 20-year trends in vision impairment among patients with diabetes suggests the rate of decline in vision impairment began to plateau in 2012 and may be on the rise in recent years.

New research from a review assessing risk of long COVID in patients with diabetes suggests the risk of developing long COVID in these patients could be more than 4-fold greater than the risk among patients without diabetes.

W. Timothy Garvey discusses the results of a study leveraging data from STEP 1 and STEP 4 to determine the reduction in 10-year risk of type 2 diabetes seen with use of semaglutide 2.4 mg vs placebo therapy.

Data from the AWARD-PEDS study presented at ADA 2022 suggest once-weekly dulaglutide could improve glycemic control in youth with type 2 diabetes, with a safety profile consistent with that observed in adult patients.

A greater reduction in UACR was observed with finerenone in patients taking GLP-1RA at baseline.

An analysis of SURPASS-4 data presented at ADA 2022 details the apparent reduction in progression of chronic kidney disease observed with use of tirzepatide compared to insulin glargine in the phase 3 trial, with a 41% reduction in progression of CKD in T2D.

During the opening press conference, Endocrinology Network got perspective from a trio of American Diabetes Association executives on the prospect of tirzepatide as an agent for combatting both diabetes and obesity.

Ahead of ADA 2022, our editorial staff offers a quick glimpse into some of the hot topics to look out for ahead of the American Diabetes Association's 82nd Scientific Sessions, including new approaches to managing renal risk, a potential game-changer in obesity, and more.

Naomi Fisher, MD, offers perspective on the changing landscape of diabetes management and how the addition of new agents to the ADA's Standards of Care might impact care of patients.

The FreeStyle Libre 3 system, which is billed by Abbott as the world's smallest, thinnest, and most accurate 14-day glucose sensor, received FDA clearance on May 31 and is expected to be available in participating pharmacies later this year.

The American Diabetes Association released updates to their Standards of Care to reflect new data regarding the cardiovascular and renal benefits of agents, including finerenone and SGLT2 inhibitors.

An analysis of data from more than 75,000 patients with diabetic kidney disease details the risk of fracture among new users of SGLT2 inhibitors compared to new users of DPP-4 inhibitors.

In his most recent column, Dr. Gregory Weiss provides breaks down a recent study that provided an overview of all-cause and cause-specific mortality among patients with diabetes before and during the COVID-19 pandemic.

Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include the approval of tirzepatide, news from AACE & ATTD, and a pair of podcast episodes.

Data from an analysis of follow-up data from the landmark DPPOS study provide insight into the apparent lack of cardiovascular risk reduction provided to patients with prediabetes from metformin and lifestyle interventions.

In a recent column, Gregory Weiss, MD, provides perspective on recent data detailing the potential impact optimal diabetes management can have on the patient- and societal-level toll imposed by diabetic eye disease.

Analysis of UK Biobank data combined with a meta-analysis of published literature provides clinicians with an overview of the relationship between type 2 diabetes and accelerated neurocognitive decline.

Using 21 years of follow-up data from more than 3000 patients with prediabetes, results of the DPPOS study demonstrate metformin use and lifestyle intervention reduced the risk of progressing to T2D, but did little to reduce the long-term risk of cardiovascular disease in these patients.

An analysis of data from an ongoing, prospective cohort study in China suggests arterial stiffness, as measured by baPWV, was a better predictor of type 2 diabetes risk than blood pressure measurements.

In this episode of Diabetes Dialogue, hosts Drs. Isaacs and Bellini take a deep dive into the tirzepatide approval, including discussions around the mechanism of action, dose titrations, and where it might fit in the upcoming ADA standards of care. Later in the episode, hosts recap their experiences from AACE 2022, which saw the release of new guidelines for NAFLD.

A systematic review and meta-analysis of 7 trials provide a detailed overview of the reductions in HbA1c and body weight, as well as the safety, of tirzepatide in various doses compared against placebo and other diabetes medications from clinical trials.

Implementation of the USPSTF 2021 and ADA 2022 guidelines would increase screening eligibility by approximately 6 to 7 percentage points.

Diabetic ketoacidosis increased the likelihood of in-hospital mortality by 61%, the likelihood of major adverse cardiovascular events by 56%, and a likelihood of 30-day readmission by 12% among patients hospitalized with heart failure in the US.

An analysis of data from more than 11,000 patients in China suggests arterial stiffness could be a better predictor of type 2 diabetes risk than other traditional risk factors, such as hypertension.